Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of EMD 525797 (DI17E6) in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer
2010-021529-11Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of abituzumab in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Merck KGaA. Primary endpoint: Progression-free survival (PFS). Started Jan 2011; status: completed.
02
Drugs
abituzumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2010-021529-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021529-11.